Nuvation Bio Stock: A Strong Company Now Fairly Priced (NYSE:NUVB)

Core Insights - The market has significantly undervalued Nuvation Bio (NUVB), particularly its drug Ibtrozi, which is aimed at treating ROS1-positive non-small cell lung cancer (NSCLC) [1] - The author believes that there is a substantial opportunity for growth in small- and mid-cap companies like Nuvation Bio, which can be identified through fundamental analysis [1] Company Analysis - Nuvation Bio's stock was initially acquired at approximately $2.50 per share, indicating a strategic entry point based on perceived undervaluation [1] - The focus on Ibtrozi highlights the company's potential in the oncology market, specifically targeting a niche segment of NSCLC patients [1] Investment Strategy - The investment approach emphasizes identifying reasonably priced companies with long-term growth prospects, as well as those with potential for exponential growth [1] - The author advocates for a disciplined investment strategy that combines education in accounting and financial principles with a suitable temperament for investing [1]